文献速递妇科

子宫内膜癌中TP53突变与p53表达异常:与种族及结局的关联

TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
PubMed 文献 · Gynecol Oncol · 2023-09-23

这项多中心队列研究评估了种族、TP53突变、p53表达与组织学类型之间的关联,以探讨子宫内膜癌的种族生存差异。黑种人患者较白种人患者更常见TP53突变(71.7% vs 49.7%)和p53异常(71.1% vs 53.2%)。TP53突变和p53异常均与更差的生存结局相关,校正后种族与生存无关联。

要点

  • 黑种人子宫内膜癌患者TP53突变率(71.7% vs 49.7%)和p53异常率(71.1% vs 53.2%)均高于白种人患者。
  • TP53突变患者无进展生存(HR 2.73)和总生存(HR 2.20)均劣于TP53野生型患者。
  • p53异常患者无进展生存(HR 2.01)和总生存(HR 1.61)均劣于p53野生型患者。

核心结论

  • 黑种人患者更常见TP53突变和p53异常的子宫内膜癌, these subtypes与更差生存相关,可能 contribuir to种族生存差异。

研究设计与样本

  • 多中心队列研究,纳入子宫内膜癌分子靶向治疗联盟数据库中具有二代测序数据的晚期或复发性子宫内膜癌黑种人和白种人患者。

主要发现

  • 黑种人患者较白种人患者TP53突变率更高(N=727,71.7% vs 49.7%,p<0.001),p53异常率更高(N=362,71.1% vs 53.2%,p=0.003)。
  • TP53突变患者较TP53野生型患者无进展生存更差(HR 2.73,95%CI 1.88-3.97),总生存更差(HR 2.20,95%CI 1.77-2.74)。
  • p53异常患者较p53野生型患者无进展生存更差(HR 2.01,95%CI 1.22-3.32),总生存更差(HR 1.61,95%CI 1.18-2.19)。
  • 校正TP53突变和p53表达后,种族与生存结局无关联。
  • 最常见的TP53变异位点为R273(n=54)、R248(n=38)和R175(n=23),其频率无种族差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multi-center cohort study assessed associations between race, TP53 mutations, p53 expression, and histology to investigate racial survival disparities in endometrial cancer (EC). METHODS: Black and White patients with advanced or recurrent EC with Next Generation Sequencing data in the Endometrial Cancer Molecularly Targeted Therapy Consortium database were identified. Clinicopathologic and treatment variables were summarized by race and compared. Overall survival (OS) and progression-free survival (PFS) among all patients were estimated by the Kaplan-Meier method. Cox proportional hazards models estimated the association between race, TP53 status, p53 expression, histology, and survival outcomes. RESULTS: Black patients were more likely than White patients to have TP53-mutated (N = 727, 71.7% vs 49.7%, p < 0.001) and p53-abnormal (N = 362, 71.1% vs 53.2%, p = 0.003) EC. Patients with TP53-mutated EC had worse PFS (HR 2.73 (95% CI 1.88-3.97)) and OS (HR 2.20 (95% CI 1.77-2.74)) compared to those with TP53-wildtype EC. Patients with p53-abnormal EC had worse PFS (HR 2.01 (95% CI 1.22-3.32)) and OS (HR 1.61 (95% CI 1.18-2.19)) compared to those with p53-wildtype EC. After adjusting for TP53 mutation and p53 expression, race was not associated with survival outcomes. The most frequent TP53 variants were at nucleotide positions R273 (n = 54), R248 (n = 38), and R175 (n = 23), rates of which did not differ by race. CONCLUSIONS: Black patients are more likely to have TP53-mutated and p53-abnormal EC, which are associated with worse survival outcomes than TP53- and p53-wildtype EC. The higher frequency of these subtypes among Black patients may contribute to survival disparities.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Whelan K, Dillon M, Strickland KC, et al. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecol Oncol. 2023. PMID: 37748270. doi:10.1016/j.ygyno.2023.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。